Impax Payment Was Meant To Dodge Competition, FTC Says

Drugmaker Impax Laboratories Inc. accepted an illegal payment from Endo Pharmaceuticals Inc. in exchange for delaying the market entry of Impax’s generic form of Endo’s opioid pain medication Opana ER, the U.S. Federal Trade Commission said Friday…

Read this piece in its entirety at Law360.

Comments

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s